This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Universal Health (UHS) Q1 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Universal Health's (UHS) first-quarter earnings reflect pre-tax unrealized loss and higher expenses.
Universal Health Services (UHS) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of -33.20% and -2.84%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Universal Health's (UHS) Q1 Earnings: What is in Store?
by Zacks Equity Research
Universal Health's (UHS) first-quarter results are likely to reflect better revenues, partially offset by the COVID-19 impact.
MEDNAX Plunges More Than 54% YTD: Will the Stock Rebound?
by Zacks Equity Research
Even though MEDNAX (MD) endures the COVID-19 impact on global economy, it holds high prospects to revive its fortunes by virtue of its solid fundamentals.
Community Health Repeals 2020 Outlook Amid Coronavirus Woes
by Zacks Equity Research
Community Health (CYH) withdraws its current-year guidance amid prevalent market volatility induced by the COVID-19 spread.
Universal Health Plunges 31.4% YTD: Will It Bounce Back?
by Zacks Equity Research
Even though Universal Health (UHS) suffers the COVID-19 impact on global economy, it holds potential to stage a comeback by virtue of its solid fundamentals.
Tenet Healthcare (THC) Gets Rating Actions From Moody's
by Zacks Equity Research
Tenet Healthcare (THC) gets specific rating actions from credit rating agency Moody's. The outlook of the ratings is stable.
Tenet Heathcare Scraps Q1 & 2020 Guidance Amid Coronavirus Chaos
by Zacks Equity Research
Tenet Heathcare (THC) nullifies its first-quarter and 2020 outlook due to the COVID-19 pandemic.
Universal Health Services (UHS) Down 28.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Universal Health Services (UHS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MEDNAX Withdraws Q1 & 2020 Guidance Due to Coronavirus Woes
by Zacks Equity Research
MEDNAX (MD) takes back its first-quarter 2020 and preliminary full-year outlook due to the COVID-19 effect.
Coronavirus-Hit Hospital Stocks Gain on Senate Stimulus Help
by Sapna Bagaria
The stimulus bill will offer the much-required financial relief to COVID-19-plagued hospitals and lead to their share price appreciation.
Acadia Healthcare Cancels U.K. Unit Sale on Coronavirus Crisis
by Zacks Equity Research
Acadia Healthcare (ACHC) dismisses plan to sell its U.K. business due to the economic uncertainty caused by coronavirus outbreak.
Tenet Healthcare Down 60.6% YTD: Should You Buy the Dip?
by Zacks Equity Research
Tenet Healthcare (THC) stock down following recommendations to keep elective procedures on hold due to coronavirus outbreak.
Chips Are Down for Hospitals on Coronavirus-Led Business Woes
by Sapna Bagaria
Stocks of hospital companies display a persistent downtrend as they put elective procedures on a back burner to brace up for the fight against a potential spike in coronavirus cases.
Universal Health Continues to Bank on Segmental Benefits
by Zacks Equity Research
Universal Health (UHS) thrives on its strong Acute Care and Behavioral platform segments.
Acadia Healthcare Gains From UK Unit Sale, Solid US Business
by Zacks Equity Research
Acadia Healthcare (ACHC) is well poised for growth on several organic and inorganic growth efforts in U.S. business and the ongoing sale proceedings of U.K. operations.
Universal Health's (UHS) Q4 Earnings Surpass, Improve Y/Y
by Zacks Equity Research
Universal Health's (UHS) Q4 results reflect higher revenues and solid segmental contributions.
Universal Health Services (UHS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 6.90% and 0.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
What in Store for Universal Health's (UHS) Q4 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q4 results are likely to reflect gains from both its Acute Care and Behavioral Health segments.
Dose of Bright Near-Term Outlook From Medical-Hospital Industry
by Sapna Bagaria
Investment in technology, an aging population and continuous consolidation offers attractive growth opportunity for the industry.
Why Hold Strategy is Apt for Universal Health (UHS) Now
by Zacks Equity Research
Universal Health (UHS) is well-positioned to reap benefits for investors on the back of its rising top line, capital strength and solid performances at both Acute Care and Behavioral Health segments.
HCA Healthcare Acquires Valify to Rein in Medical Costs
by Zacks Equity Research
HCA Healthcare (HCA) completes the buyout of technology company Valify to identify opportunities for reducing expenses.
Why Should You Hold HCA Healthcare in Your Portfolio Now?
by Zacks Equity Research
Riding high on its growing revenues and a firm capital position, HCA Healthcare (HCA) holds potential to reap benefits for investors.
HCA Healthcare Acquires Galen, Expands Nursing Schools
by Sapna Bagaria
The acquisition of a majority ownership of Galen College of Nursing provides HCA Healthcare (HCA) with consistent availability of nurses.
MEDNAX Expands Further in Florida With Radiology Affiliation
by Zacks Equity Research
MEDNAX (MD) forms an association with Boca Radiology Group to strengthen its radiology business in Florida.